Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)
Health Care – PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 414
- Market Cap
- $8.0B
About Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
SentiSense also tracks daily options readings for Rhythm Pharmaceuticals, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Rhythm Pharmaceuticals, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.